Aspen shares jump to highest since January 2019 on Covid-19 treatment breakthrough
The pharmaceutical manufacturer is a leading global supplier of dexamethasone, which trials show cuts the risk of death among some Covid-19 patients
Aspen Pharmacare jumped to an almost 17-month high after research showed that a drug that it is a major supplier of reduced deaths in critically ill Covid-19 patients.
The JSE-listed pharmaceutical manufacturer is a leading global supplier of dexamethasone, which it manufactures at sites in SA, Germany and Australia. Scientists from Oxford University’s Recovery Trial on Tuesday announced that the drug cut the risk of death among ventilated patients by a third, and reduced mortality by a fifth in those receiving oxygen. The research has been hailed as a breakthrough, as it is the first evidence of an effective treatment for Covid-19 patients with severe breathing problems...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.